

# Examples of Respiratory Compromise

Conference on Respiratory Insufficiency  
February 26 / 27<sup>th</sup>, 2015

Peter S. Marshall, M.D. MPH  
Pulmonary, Critical Care & Sleep Section  
Department of Medicine  
Yale School of medicine

# Introduction

- Describe clinical presentation of common subsets of respiratory compromise
- Discuss pathophysiology
- Discuss epidemiology and risk factors for poor outcomes
- Offer examples of predictive models / tools
- Propose gaps on knowledge

# Control of breathing and airway protection

- 33 yo male presents to the emergency department with severe lower back pain after an MVA. His evaluation includes normal vitals & basic blood work. His toxicology reveals only benzodiazepine which he is prescribed. There is no evidence of fracture on radiography or CT.
- He is given fentanyl in the ER and the trauma service is called
- He is admitted to the general medical ward for pain control and an MRI
- He is prescribed ATC morphine and prn doses IV for severe / breakthrough pain in addition to NSAIDs.
- Four hours later he is found apneic and pulseless.
- ACLS is performed and he is intubated. The CXR shows a new infiltrate.


# Control of breathing and airway protection

- Hallmarks
    - Central depression of respiratory drive
    - Loss of tone in upper airway
    - Blunting of airway clearance mechanisms
  - Results
    - Impaired gas exchange (hypercapnia and hypoxemia)
    - Aspiration of upper pharyngeal contents into lower airways
    - Inability to clear lower airways of debris
- Respiratory failure → cardiopulmonary arrest → death

# Central respiratory depression – Opiates as paradigm

- 1.3 % risk of developing critical respiratory event post-op
- 1 % of those receiving fentanyl experienced adverse event including respiratory depression in ED
- Use of PCA with lock-outs lowers risks to 0.2 – 0.5 %
- Fatal events occur in the setting of inadequate and adequate monitoring


# Overview of control of respiration



# Mechanism of CNS opiate respiratory depression


- MEDULLA: Neurokinin 1 receptors (NK-1 R) expressing neurons in pre-Botinger complex mediate inspiration, inhibited by opiates
- CORTEX: Reduced sensitivity of chemoreceptors to changes in pCO<sub>2</sub> are well described among opiate addicted patients
- PONS: Suppression of acetyl-choline release in medial pontine reticular formation → “sleep-like” state

# Mechanisms of central depression





# Forces controlling patency of upper airway



# Other effects

- Opioid receptors on bronchioles
  - Bronchoconstriction → increase in  $R_{aw}$
- Abdominal and chest wall rigidity
  - Especially at high doses (e.g. Stiff chest in fentanyl boluses)
  - Reduced phrenic nerve and diaphragm activity
  - Reduced  $V_t$

# Central depression by opiates: Biological factors

- Age – lower rates of clearance
- Gender – females - up to 25 % higher levels of oxycodone
- Ethnicity – some groups have enhanced clearance (allelic variants in CYP2D6); rapid metabolizers run greater risk of respiratory depression than poor metabolizers
- Co-morbidities – Hepatorenal impairments affect clearance (fentanyl and methadone minimally effected by liver or renal impairment)
- Drug interactions
  - Potentiation: Buprenorphine and opiates or benzos and opiates
  - Opiates and cardiac meds

## Opiate induced resp failure: patient characteristics / profile

- Sleep disordered breathing
- Morbid obesity
- Snoring
- Older age
- Opioid naïve
- Post-surgical (esp. upper abdominal, chest wall or upper airway)
- Increased opioid dose need
- Prolonged anesthesia
- Use of additional sedating drugs
- Prior cardio-pulmonary disease, other major organ dysfunction (liver, renal)
- Smoker

# Risk factors for respiratory failure / death


- Upper airway obstruction
- Chronic use of opioids (chronic blunting of chemoreceptors)
- Abnormal metabolism (e.g. mutation in CYP2D6 causing rapid metabolism of codeine to active metabolite)
- Joint Commission (Sentinel event alert, August 2012)
  - 11% Excessive dosing (esp. opioid naïve), drug-drug interactions, adverse reactions
  - 47% medication errors
  - 29% inadequate monitoring

# Monitoring for central depression


- High frequency of nursing assessments at outset
  - Level of conscientiousness
  - Vitals
  - Pain scores
- Sudden death can occur despite monitoring
  - Can we identify susceptible individuals up front?
  - Is this more related to aspiration which is more difficult to detect and more common than we believe?
  - How do we monitor outside of ICU / recovery room?
  - Do we need more objective methods of monitoring outside of ICU / PACU?

# Acute lung injury / ARDS

- Berlin Definition – JAMA 2012
  - Onset with 1 week
  - Bilateral opacities
  - Not explained by cardiac failure (objective assessment – TTE for example)
  - Poor oxygenation
    - Mild – P/F 200 – 300 on  $\geq$  PEEP 5
    - Moderate – P/F 100 - 200 on  $\geq$  PEEP 5
    - Severe – P/F  $<$  100 on  $\geq$  PEEP 5







## Risks Factors for Mortality in ARDS/ALI


---

Risk	Coefficient
Age >65	1.98
Cirrhosis	1.75
HIV	2.75
Malignancy	1.76
Transplant	3.67
Sepsis	1.02

Zilberberg, M.D. and Epstein, S.K. Am J Respir Crit  
Care Med; 1999; 157:1159

# Pneumonia as model for Acute lung injury

- Comprise large fraction of patients with ARDS
- Some are admitted and progress to insufficiency and failure
- Many tools to predict progression – not perfect




# PNA - pathophysiology

- V/Q mismatch
- Airway obstruction – secretions, bronchospasm
  - Increased resistive W.O.B.
- Restrictive physiology – consolidation, effusion, atelectasis
  - Increased elastic W.O.B.
- Diffusion impairment
- Severe multi-lobar PNA → ARDS
  - Physiological shunt (severe hypoxemia)
  - Severe restrictive physiology / reduced lung compliance (markedly increased WOB)
  - Increased dead-space ventilation (hypercapnia)


# Shunt Physiology in ARDS

---




# Hydrostatic & Non-hydrostatic Pulmonary Edema

---



# Lung Compliance in ARDS

---






# PNA – Progression / stages

- Clinical signs and symptoms
  - Cough
  - Dyspnea
  - Pleuritic chest pain
  - Fever / chills / sweats / hypothermia
  - Headache
  - Malaise
- Progression
  - Systemic Illness
    - Sepsis
    - Severe sepsis / septic shock / ARDS
  - Pulmonary
    - Respiratory insufficiency
    - Respiratory failure
    - Complications: ARDS, empyema, necrotizing pna, abscess, BP fistula, fibrosis, bronchiectasis

CRIT CARE 2012	PSI	CURB 65	CRB-65	CURB	CORB	ATS/IDSA	SMART-COP	SCAP	REA-ICU
MV						X			
Shock	X					X			
Age	X	X	X					X	X
Gender	X								X
Co-morbid	X								X
Mental status	X	X	X	X	X	X	X	X	
HR	X					X	X		X
T	X					X			
RR	X	X	X	X	X	X	X	X	X
BP	X	X	X	X	X	X	X	X	
P / F	X				X	X	X	X	X
pH	X							X	X
infiltrate	X					X		X	X
Na	X								X
Gluc	X								
Urea / Albumin		X (U)		X (U)		X (U)	X (ALB)	X (U)	X (U)
WBC / PLT						X			X (WBC)

## Pooled discriminative performance

- Newer rules (ATS/IDSA 2007, SCAP and SMART-COP) better at predicting ICU admission
- High NPV is hallmark, however



# PNA - Summary

- Many prediction rules exist – likely under-utilized?
- Often designed to predict 30 day mortality
  - Prediction of shorter term progression is more useful
  - Newer models focus on shorter term escalation of care as end-point
- Lack PPV needed to confidently identify those for closer monitoring
- High NPV - can identify those with low risk of progression to respiratory insufficiency, respiratory failure, ARDS, severe sepsis, shock
  - Helpful with triage
- Do we need to incorporate biomarkers or more physiologic data?
- Do these rules apply to non-bacterial forms of pna?

# Bronchospasm – COPD and Asthma admissions

For Asthma admissions:

- Approximately 500,000 admissions annually
- 1.7 – 2.0 % of all ICU admissions
  - Approximately 30 % require intubation
  - Mortality rate once intubated ranges between 6 and 42%
  - Mortality much higher in intubated patients (to be avoided)
- 5000 deaths annually

# Mortality risk factors for patients with SA

- Prior intubation
- Frequent hospitalizations
- Prior ICU admission
  
- Predicting mortality
  - **Less than 50 %** of asthma mortalities possess these features
    - Risk stratification difficult
    - Few formal tools exist that predict in-hospital deterioration


# Pathophysiology of acute severe asthma

- Three hallmarks
  - Inflammation
  - Bronchoconstriction
  - Mucus production
- Results in:
  - Increased airway resistance
    - Increased resistive WOB
  - Air trapping (unable to empty to baseline FRC)
    - Dynamic hyperinflation
    - Increased elastic recoil
    - Increased elastic WOB
  - Reduced  $V_t$ 
    - Increased dead-space → hypercapnia
  - Mucus plugging of small airways
    - V/Q mismatch → hypoxemia

# Dynamic hyperinflation

With each respiratory effort:

- More air is trapped and there is increased end exp volume
- $V_t$  is smaller  $\rightarrow$  increased dead-space ventilation
- The elastic recoil of the lung is increased
- *Also increase in intra-thoracic pressures = **Auto-PEEP***





# Extra-pulmonary consequences

- Lactic acidosis
  - Increased WOB (resistive and elastic)
  - Anaerobic metabolism in the setting of hypoxemia
  - Side-effect of high doses of SABA
- Reduced Cardiac output, hypotension
  - Dynamic hyperinflation → auto-PEEP (increased intra-thoracic pressures)
  - Reduce venous return to RV
  - Rapid RV filling during exaggerated inspiratory efforts → septal displacement into LV, impaired LV filling / reduced SV
  - Increased RV afterload due to auto-PEEP → worsening of IV septal displacement
  - Clinical manifestation = Pulsus paradoxus
    - Exaggerated reduction in SBP during inspiration (> 12 – 15 mmHg)
- Myocardial ischemia
  - Increased WOB
  - Rapid HR due to SABA, reduced SV, anxiety
  - Hypotension

**TABLE 3. Classifying Severity of Asthma Exacerbations**

Variable	Severe Exacerbation*	Imminent Respiratory Arrest
Symptom		
Dyspnea	At rest	Unable to speak
Speech	Single words, no phrases	Lethargic, confused,
Alertness	Agitated	Obtunded
Signs		
Respiratory rate	>30/min	<10 breaths/min
Heart rate	>120/min	<60/min
Pulsus paradoxus	>25 mm Hg	Normal/low
Use of accessory muscles	Evident	Paradoxical
Wheeze	Present–loud	“Silent chest”
Functional assessment		
PEF	<40% predicted	<25% predicted
paO <sub>2</sub>	<60 mm Hg	N/A
paCO <sub>2</sub>	>42–45 mm Hg	N/A
SaO <sub>2</sub>	<91%	N/A

NHBLI, Guidelines for the diagnosis and management of asthma

---

**TABLE 2.** Risk Factors for Death From Asthma

---

**Asthma History**

---

- Previous severe exacerbation (intubation or ICU admission)
- Two or more hospitalizations in last year
- Three or more emergency department visits in last year
- Hospitalization or emergency department visit within past month
- Greater than 2 canisters of short-acting beta agonist per month
- Difficulty perceiving asthma symptoms or severity of exacerbations
- Other risk factors: lack of action plan, sensitivity to alternaria
- Previous severe exacerbation (intubation or ICU admission)
- Two or more hospitalizations in last year

**Social History**

---

- Low socioeconomic status
- Illicit drug use
- Major psychosocial problems
- Inner-city residence

**Comorbidities**

---

- Cardiovascular disease
  - Other chronic lung disease
  - Chronic psychiatric disease
- 

NHBLI, Guidelines for the diagnosis and management of asthma

# Evaluation

- History
- HR, RR, Pulse
- Peak flow, FEV1
- Pulsus paradoxus
- Oxygen saturation
- ABG
- Assessment of breathing pattern
- Assessment of volume status
- Assessment of mental status
- Response to initial therapy

# Asthma exacerbations - Summary

- Risk factors for poor outcomes exist but are inconsistently present in those who deteriorate / die
- Extra-pulmonary manifestations suggest poor outcomes
- Deterioration can be sudden / rapid
- Mechanical ventilation of patients with asthma adds to their risk
- Should a formal tool for be developed to predict decline?
- Could enhanced monitoring of these patients impact mortality / outcomes?

# Pulmonary embolus

- Cardiovascular and respiratory deterioration possible
- In those without overt hemodynamic instability it can be difficult to know who is “sick”
- Management / monitoring of the hemodynamically stable patient is not straightforward

# The PE story we all have heard

- 70 yo male with a h/o HTN and COPD presents to the ED with pleuritic chest pain and dyspnea for two days.
- P105, BP 110/65, RR 22 O2 sat 92% r/a, Afebrile
- No adventitious sounds on lung exam, heart exam tachy, extremities cool with no edema
- Trop-I 0.5 → ?, EKG – sinus tach, inv T-waves across precordium
- CTA – RUL lobar embolus; IV flattening
- He is admitted to a monitored bed
- TTE – mild RV HK with RA and RV enlargement; IV septal flattening
  - A second TTE on HD # 2 is unchanged
- He is placed on LMWH immediately and given Coumadin on HD #2
- Discharged with 4 days of LMWH on HD #2
- Within 12 hours he is brought back to the hospital by EMS after a PEA arrest and expires in the ED

# Epidemiology

- 600,000 PE's per year in the US
- Accounts for 100,000 to 200,000 deaths
- Mortality rates:
  - 13.0 - 17.5 % at 3 months across all severities
- Most deaths within 60-90 minutes




# Recognized Groups by Risk


- High risk (Massive) - hemodynamic compromise: 22%
  - In **past**,
    - Massive used to describe angiographic score for occlusion
    - V/Q obstruction score (Miller Index)
  - 35 – 75% mortality
- Intermediate risk (Sub-massive) = RV dysfunction, no hemodynamic compromise: 31%
  - 5 – 25% mortality
  - Difficult to distinguish clinically from Low risk
- Low risk PE: 47%
  - Often asymptomatic
  - Incidental finding; small clots in distal vessels
  - 1 – 4 % short term mortality

- 
- Major PE = Intermediate and High risk PE

# Outcomes in Pulmonary Embolism



# Hemodynamics



# IMPAIRED GAS EXCHANGE


- **V / Q mismatch**
- **Reduced mixed-venous saturation**
- **Impaired diffusion**
- Right – to – left shunt
- Dead space ventilation → hypercapnia?

---

- Hypoxia adds to increases in PVR

# Markers used to assess severity

- **Vital signs:** BP, HR, (RR)
  - **Troponin** released in response to low CPP & myocardial injury
    - CPP = MAP – RV intra-cavitary pressure
    - Others = HFABP
  - **Oxygen saturation**
  - **Co-morbidities**
  - **Clot burden:** Especially co-existing DVT
  - RV strain:
    - **BNP** released in response to RV pressure load / dilation
    - **TTE**
    - **EKG**
    - **CTA**
- > Ideally we want to detect deterioration prior to drop in BP**



## PESI Classes & Mortality

### PE Severity Index (PESI)

- Weighted variables (11)
- Easy to obtain

Class	Points	Mortality (30 day)
I	0 - 65	0 – 1.6
II	66 - 85	1.7 – 3.5
III	86 - 105	3.2 – 7.1
IV	106 - 125	4.0 – 11.4
V	> 125	10 – 24.5

- Prospectively validated
- Elevated risk possible w/out hemodynamic compromise
- Most helpful for triage decisions (Low risk = I & II; High risk = III, IV and V)

## Simplified PESI (SPESI)

**Table 1. Original and Simplified Pulmonary Embolism Severity Index (PESI)**

Variable	Score	
	Original PESI <sup>a</sup>	Simplified PESI <sup>b</sup>
Age >80 y	Age in years	1
Male sex	+10	
History of cancer	+30	1
History of heart failure	+10	1 <sup>c</sup>
History of chronic lung disease	+10	
Pulse ≥110 beats/min	+20	1
Systolic blood pressure <100 mm Hg	+30	1
Respiratory rate ≥30 breaths/min	+20	
Temperature <36°C	+20	
Altered mental status	+60	
Arterial oxyhemoglobin saturation level <90%	+20	1

- Predicts 30 Day Mortality
- 11 variables to 6

SPESI

Score of 0 = Low risk → 1.1%

Score 1 or greater = High risk → 8.9%

PESI

Low risk → 2.1%


High risk → 14%

Jimenez et al, Arch Int Med 2010



## ROC curves of SPESI and PESI (30 day mortality)

- SPESI has greater sensitivity (96 v. 88)
- PESI and SPESI have similar NPV (97 v. 99)
- PESI and SPESI have similar PPV (10.9 v. 10.9)
- SPESI has similar operating characteristics yet is easier to use
- Does not tell us about in-hospital decline



**Figure.** Receiver operating characteristic curves for 30-day mortality for the original and the simplified Pulmonary Embolism Severity Index (PESI) in this study's derivation cohort.

## PE Risk Score: Identification of Intermediate-risk patients with acute symptomatic PE

Goal: Identify normotensive patients at higher risk for complications (consideration of aggressive therapy?)

Predictor	Points
SBP 90 – 100	2
Elevated Troponin	2
RVD (TTE or CTA*)	2
HR > 110	1

\*PROTECT criteria for CTA

Bova et al Eur Resp J v44 2014

Stage	Points	30 day**
I	0 - 2	4.2 %
II	3 - 4	10.8 %
III	> 4	29.2 %

\*\*Cumulative incidence of 30 Day PE related complications (PE related death, recurrent PE, hemodynamic collapse, mechanical ventilation)


## PE Risk Score: Identification of Intermediate-risk patients with acute symptomatic PE

30 day cumulative complication rate for symptomatic PE stratified by stage

Stage	In Hosp	30 day**	30 day mortality
I	<b>3.6</b>	4.2	1.7
II	<b>9.7</b>	10.8	5.0
III	<b>28.0</b>	29.2	15.5

In-hospital events contribute greatly to events at 30 days

Bova et al Eur Resp J v44 2014



Did not account for bleeding risk or for thrombotic burden (i.e. presence of DVT)

# PE predictors of poor outcome / clinical deterioration

- Validated models / scoring systems exist
- Models have good NPV but poor PPV so, by themselves, can not efficiently inform decisions about aggressive therapy or enhanced monitoring
- Models allow us to classify patients as low risk with reasonable certainty
  - Allows outpatient management of PE
- Models often not applicable to the in-hospital setting (outcomes at 30 days)
- PE risk score (Bova et al, Eur Resp J 2014) alludes to in-hospital events but requires prospective validation for this end-point

# Afferent inputs from chemo receptors, stretch receptors and baroreceptors

**NTS** – nucleus tractus solitarius – relays info on  $pO_2$  from carotid sinus  
**RTN** – retrotrapezoid nucleus – main site of cerebral chemoreception  
**MRN** – Medullary raphe nucleus – senses changes in pH and  $pCO_2$

